WallStreetZenWallStreetZen

NASDAQ: ALKS
Alkermes PLC Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Alkermes earnings were $367.1M for the trailing 12 months ending Dec 31, 2024, with 3.7% growth year over year. The latest ALKS earnings report on Dec 31, 2024 announced Q4 2024 earnings of $146.5M, up 58.6% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ALKS reported annual earnings of $367.1M, with 3.2% growth. The next ALKS earnings date is Apr 29, 2025.

ALKS past earnings growth

How has ALKS's earnings growth performed historically?

Company
3.74%
Industry
55.51%
Market
63.03%
ALKS's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
ALKS's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
ALKS's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

ALKS earnings history

Current Revenue
$1.6B
Current Earnings
$367.1M
Current Profit Margin
23.6%

ALKS Return on Equity

Current Company
27.7%
Current Industry
12.5%
Current Market
34.1%
ALKS's Return on Equity (27.7%)... subscribe to Premium to read more.
High Return on Equity Performance

ALKS undefined

Current Company
17.2%
Current Industry
5.5%
ALKS is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when ALKS announces earnings.

ALKS undefined

Current Company
29%
Current Industry
12%
ALKS has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ALKS vs Pharmaceutical Stocks

TickerEBITDAEarningsY/Y EarningsEPS
ALKS$489.79M$367.07M+3.74%$2.22
ELAN$1.39B$338.00M+30.45%$0.68
PBH$367.43M$213.94M+6.82%$4.31
PRGO$421.90M-$171.80MN/A-$1.25
ALVO$116.90M-$231.86MN/A-$0.87
View Top Pharmaceutical Stocks

ALKS earnings dates

Next earnings date
Apr 29, 2025

Alkermes Earnings Reports & History FAQ

What were Alkermes's earnings last quarter?

Alkermes (NASDAQ: ALKS) reported Q4 2024 earnings per share (EPS) of $0.90, up 32.35% year over year. Total ALKS earnings for the quarter were $146.50 million. In the same quarter last year, Alkermes's earnings per share (EPS) was $0.68.

If you're new to stock investing, here's how to buy Alkermes stock.

When does Alkermes report earnings?

The next ALKS earnings call is Invalid Date. Add ALKS to your watchlist to be reminded of Alkermes's next earnings date.

What was ALKS's earnings growth in the past year?

As of Alkermes's earnings date in Q2 2025, Alkermes's earnings has grown 3.74% year over year. This is 51.77 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 55.51%. ALKS earnings in the past year totalled $367.07 million.

Is Alkermes profitable or losing money?

As of the last Alkermes earnings report, Alkermes is currently profitable. Alkermes's net profit (also called net income) for the twelve months ending Dec 31, 2024 was $367.07 million, a 3.18% increase year over year.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.